Related Experiment Video
Updated: Jan 18, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Efficacy of Immune Checkpoint Inhibitors in the Treatment for Head and Neck Cancer Patients: A Systematic Review and
Jiao Li1,2, Nurhayu Ab Rahman1,3, Suharni Mohamad1
1School of Dental Sciences, Universiti Sains Malaysia, Health Campus, Kubang Kerian, 16150, Malaysia.
Objectives:
Checkpoint inhibitors have significantly improved outcomes in a number of malignancies. To determine the most effective course of treatment for head and neck squamous cell carcinoma (HNSCC), this systematic review evaluated the efficacy of several therapeutic approaches based on immune checkpoint inhibitors (ICIs).
Methods:
A comprehensive evaluation of the literature was conducted, looking at randomized controlled trials (RCTs) that were published in Embase, PubMed, and the Cochrane Central Register of Controlled Trials since database establishment. The risk of bias of the enrolled studies was analyzed using The Review Manager (RevMan) 5.4. Using network meta-analyses (NMA), the relative treatment effects on overall survival (OS) and progression-free survival (PFS) from qualifying randomized controlled trials were synthesized and evaluated.
Results:
Regarding OS, compared with nivolumab plus chemotherapy, chemotherapy (Hazard ratio (HR) = 2.1, 95% Confidence interval (CI): 1.2, 3.4) showed a treatment disadvantage. Meanwhile, nivolumab plus chemotherapy may represent the most efficient (57.89%) and has a lower cost among all the treatments enrolled in this study for advanced HNSCC. Regarding PFS, compared with nivolumab plus ipilimumab, nivolumab plus chemotherapy (HR = 0.4, 95% CI: 0.2, 0.8) showed treatment superiority. Additionally, nivolumab plus chemotherapy (77.18%) has the longest PFS among all interventions.
Conclusion:
Taking into account OS and PFS, the combination of nivolumab plus chemotherapy may appear to be the most effective option and is associated with a comparatively lower cost among all treatments included in this network meta-analysis, thereby recommending its use as a first-line therapy for HNSCC.
Registration:
INPLASY (2024070073).
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Related Concept Videos
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...